Strategies to define novel prostate cancer target for therapy
Table of Contents
Mark Rubin - Weill Cornell Medical College
May 21, 2012
11:00 DKFZ Main Auditorium
Host: Holger Sültmann
Biosketch Mark Rubin
Mark A. Rubin, M.D. a board-certified anatomic pathologist is Vice Chair for Experimental Research at Weill Cornell Medical College (WCMC) in New York City. He is also the Associate Director of the WCMC Cancer Center. He has over 250 peer-reviewed publications, serves on numerous Scientific Advisory Boards and is a member of the WHO Prostate Cancer Tumor Classification and the TCGA Advisory Group (NCI).
Dr. Rubin has had continuous National Cancer Institute (NCI), Department of Defense, and Prostate Cancer Foundation funding for the past 10 years and was a standing member of the Cancer Biomarkers Study Section (CBSS) for the NCI (term expired June 2011). He has played a lead role in two major NCI funded programs: the Specialized Program of Research Excellence (SPORE) and the Early Detection Research Network (EDRN)either as a Project and/or a Core leader. He established the first Tissue Microarray Core Facilities and directed Biobanks at Michigan, Harvard and Weill Cornell. He currently serves on the EDRN Steering Committee and chairs the EDRN Prostate Cancer Consortium Group. He has longstanding collaborations with all 11 Prostate Cancer SPOREs as well as established international collaborations with the Universities in Ulm (Germany), Paris (France), Innsbruck (Austria), Stockholm (Sweden), and the UHZ (Switzerland).
Dr. Rubin has made significant contributions to the field of prostate cancer research in the area of genomics and biomarker development.. Highlights from this work include the publication of the first expression profiling study in prostate cancer and the identification of important prostate cancer biomarkers A landmark discovery in 2005 resulted in the characterization of recurrent ETS rearrangements in prostate cancer involving TMPRSS2-ERG and TMPRSS2-ETV1 .This paradigm shifting work demonstrated that over 50% of prostate cancers harbor recurrent gene fusions involving an androgen driven promoter, TMPRSS2, and an ETS family member transcription factor. These finding have been validated worldwide and invigorated a new line of research trying to establish a molecular classification of prostate cancer similar to AML. Dr. Rubin continues to develop novel approaches for genomic discovery. His group was one of the first to use laser capture microdissection, tissue microarrays, oligonucleotide arrays and now Next Generation Sequencing technology for translational research. He has also been at the cutting edge of helping develop computational approaches to analyze emerging data from expression profiling and oligonucleotide arrays and Next Generation Sequencing.